Rocket Heart key facts
as of Oct 2026- Manufacturer of implantable circulatory support systems intended for cardiac function restoration.
- Rocket Heart is valued at approximately $455.2M as of Oct 2026 (last reported valuation).
- It has raised $13.8M; the latest was Later Stage VC in Aug 2025.
- Notable investors include China Aerospace Investment Holdings, Shenzhen Xingrun Asset Management.
- Status: Privately Held (backing).
Rocket Heart's last reported valuation, Nov 2023. Nothing priced has surfaced since.
- ·Watch Rocket Heart: the Monday email on marks, rounds and moves
Rocket Heart funding rounds
No funding rounds for Rocket Heart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Rocket Heart
2Rocket Heart valuation
Rocket Heart's last reported valuation was $455 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.
Rocket Heart investors
2 investors are on record for Rocket Heart, including China Aerospace Investment Holdings and Shenzhen Xingrun Asset Management.
About Rocket Heart
Manufacturer of implantable circulatory support systems intended for cardiac function restoration. The company offers miniaturized mechanical pumps, biocompatible vascular interfaces, telemetry-enabled monitoring units, and preoperative simulation tools with post-surgical training modules and clinical consultation services, serving specialized healthcare markets to deliver targeted heart failure interventions with improved patient outcomes, reduced procedural risks, and enhanced device adaptability across diverse physiological profiles.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2016
- Employees
- 13
- Website
- rocket-heart.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.